KYMR Earnings

KYMR reported its FY2025Q3 earnings on 2025-11-04, showcasing a revenue of 2.76M against an estimate of 23.55M, resulting in a -88.26% surprise. The EPS was -0.9, surpassing the expected -0.71 by -26.76%. The stock experienced a 0.32% price change on the earnings day and a -1.77% change over the next five days, reflecting market reactions to the results.

Following KYMR's FY2025Q3 earnings announcement on 2025-11-04, the stock price moved by 0.32% on the day of the release. Over the subsequent five days, it saw a -1.77% change. Historically, KYMR's stock price tends to shift by an average of 1.67% in the 10 days leading up to earnings and 7.88% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate KYMR's annual revenue to reach 10.62M, while the EPS is projected at -0.97. These estimates reflect recent revisions, with revenue estimates revised downward by -0.02% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between KYMR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.02%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, KYMR's stock price typically moves by 1.67% in the 10 days before its earnings and 7.88% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.97 and revenue of 10.62M.

The earnings call summary indicates strong financial health with extended cash runway and partnerships with major firms like Gilead and Sanofi. The Q&A section reveals management's cautious optimism and strategic trial designs, while avoiding specifics on certain aspects. The company's strategic plans, including new partnerships and financial guidance, suggest a positive outlook. Given the market cap of $1.85 billion, the stock is likely to react positively, but not dramatically, leading to a prediction of a 2% to 8% increase over the next two weeks.